Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AlphaRx Seeks Listing with TSX Venture Exchange

Abstract:
AlphaRx (OTC BB:ALRX - News) AlphaRx, a leader in the development of Nanotechnology for Drug Delivery Platforms, is pleased to announce that it has retained a Canadian investment bank to act as sponsor for the inter-listing of its shares on the TSX Venture Exchange.

AlphaRx Seeks Listing with TSX Venture Exchange

MARKHAM, ON, Canada | Posted on December 11th, 2007

"We strongly believe that being listed on a Canadian stock market will help create shareholder value. It is often difficult for Canadians to trade on certain U.S. exchanges. By inter-listing on a Canadian exchange, we are removing an obstacle," said Michael Lee, President and CEO of AlphaRx.

The TSX Venture Exchange, which is owned by TSX Group, have a strong corporate governance regime - similar to the U.S., companies have to pass published financial and sector-specific tests to list on TSX Venture Exchange.

Companies that list on TSX Venture Exchange have the added advantage of benefiting from Canada's strong dollar and healthy economy - forecasted to grow at almost double that of the U.S. in 2008 - as well as strong demand from Canadian retail and institutional investors, many of whom are used to trading small-cap stocks.

Upon approval of its listing application by the TSX Venture Exchange, AlphaRx's common stock will be dually listed on the TSX Venture Exchange in Canada as well as over-the-counter in US.

####

About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

For more information, please click here

Contacts:
Nucap Investor Relations
http://www.thenucap.com
AnthonyOrlando
Managing Partner
629 Fifth Avenue,Suite 300
Pelham, NY 10803
(914) 924-7437

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanometrics Announces Upcoming Investor Events August 3rd, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

GLOBALFOUNDRIES Delivers 8SW RF SOI Technology for Next-Generation Mobile and 5G Applications: Advanced 8SW 300mm SOI technology enables cost-effective, high-performance RF front-end modules for 4G LTE mobile and sub-6GHz 5G applications September 20th, 2017

GLOBALFOUNDRIES Unveils Vision and Roadmap for Next-Generation 5G Applications: Technology platforms are uniquely positioned to enable a new era of ‘connected intelligence’ with the transition to 5G September 20th, 2017

GLOBALFOUNDRIES Delivers Custom 14nm FinFET Technology for IBM Systems: Jointly developed 14HP process is world’s only technology that leverages both FinFET and SOI September 20th, 2017

GLOBALFOUNDRIES Introduces New 12nm FinFET Technology for High-Performance Applications September 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project